偏頭痛治療薬の世界市場2016-2020

◆英語タイトル:Global Migraine Drugs Market 2016-2020
◆商品コード:IRTNTR9324
◆発行会社(調査会社):Technavio
◆発行日:2016年5月2日
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、偏頭痛治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、偏頭痛治療薬の世界市場規模及び予測、種類別分析、治療クラス別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Migraines
A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

Technavio’s analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Allergan
• Endo International
• GlaxoSmithKline
• Impax
• Pfizer

[Other prominent vendors]
• Abbott
• Aegis Therapeutics
• Aeriel BioPharma
• Alder Biopharmaceuticals
• Amgen
• Astellas
• AstraZeneca
• Bayer
• CoLucid
• Dr. Reddy’s Laboratories
• Eisai
• Eli Lilly
• Ethypharm
• IntelGenx
• Johnson & Johnson
• Klaria
• Kowa Pharmaceuticals America
• Luitpold Pharmaceuticals
• Meda
• Merck
• OptiNose
• Pfizer
• Pozen
• Raptor
• RedHill
• SUDA
• Teva
• TG Therapeutics
• NValeant
• Winston Pharmaceuticals
• Zogenix

[Market driver]
• Growing awareness about migraine and its treatment options
• For a full, detailed list, view our report

[Market challenge]
• Lack of proper diagnosis
• For a full, detailed list, view our report

[Market trend]
• Antimigraine devices and headbands
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Types
• Cause
• Management
• Epidemiology
• Economic burden

PART 06: Pipeline analysis
• Semprana
• Rizaport
• Sumatriptan
• DFN-11
• Lasmiditan
• SUD001
• AMG 334
• DFN-02

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of treatment
• Preventative
• Abortive

PART 09: Market segmentation by therapeutic class
• Triptans
• Ergot alkaloids
• Other

PART 10: Geographical segmentation
• Global migraine drugs market by geographical segmentation 2015-2020
• Migraine drugs market in Americas
• Migraine drugs market in EMEA
• Migraine drugs market in APAC

PART 11: Market drivers
• Growing awareness about migraine and its treatment options
• Tentative approval of pipeline candidates
• High unmet needs
• Increased prevalence of migraines

PART 12: Impact of drivers

PART 13: Market challenges
• Lack of proper diagnosis
• Adverse effects of drugs
• Increased preference for alternative therapies
• Generic penetration

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Antimigraine devices and headbands
• Increase in R&D
• Novel product innovations
• Strategic alliances

PART 16: Vendor landscape
• Competitive scenario
• Allergan
• Endo International
• GlaxoSmithKline
• Impax
• Pfizer
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Percentage of migraine sufferers worldwide by gender
Exhibit 03: Global migraine drugs market: Pipeline portfolio
Exhibit 04: Global migraine drugs market 2015-2020 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Preventative medications based on efficacy of drugs
Exhibit 07: Medications used based on severity of migraines
Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015
Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015
Exhibit 10: Market share of triptans by ROA 2015
Exhibit 11: Global migraine drugs market by geography 2015
Exhibit 12: Global migraine drugs market by geography 2015-2020 ($ millions)
Exhibit 13: Migraine drugs market in Americas 2015-2020 ($ billions)
Exhibit 14: Migraine drugs market in EMEA 2015-2020 ($ millions)
Exhibit 15: Migraine drugs market in APAC 2015-2020 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 17: Percentage of population diagnosed with migraine in US 2014
Exhibit 18: Impact of drivers and challenges
Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions)
Exhibit 20: Allergan: Key takeaways
Exhibit 21: Endo International: Key takeaways
Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions)
Exhibit 23: GlaxoSmithKline: Key takeaways
Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions)
Exhibit 25: Impax: Key takeaways
Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
Exhibit 27: Pfizer: Key takeaways



【掲載企業】

Allergan, Endo International, GlaxoSmithKline, Impax, Pfizer, Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, Zogenix.

【レポートのキーワード】

偏頭痛、治療薬、頭痛治療、鎮痛剤、抗片頭痛薬、トリプタン系薬剤、麦角アルカロイド

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[偏頭痛治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[偏頭痛治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆